Apr 21, 2022 5:00 pm EDT Expanded SEER Registries Dataset Shows Improved Survival for DecisionDx®-Melanoma Tested Patients Compared to Untested Patients
Apr 20, 2022 5:00 pm EDT Castle Biosciences to Present Data at the 18th European Association of Dermato Oncology (EADO) Congress
Apr 18, 2022 7:00 am EDT Castle Biosciences Presents Data on Its Inflammatory Skin Disease Pipeline Test at the 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference
Apr 5, 2022 5:00 pm EDT Castle Biosciences to Present at the 21st Annual Needham Virtual Healthcare Conference
Mar 29, 2022 5:00 pm EDT Castle Biosciences Receives Advanced Diagnostic Laboratory Test (ADLT) Status for TissueCypher® Barrett’s Esophagus Test from the Centers for Medicare & Medicaid Services (CMS)
Mar 25, 2022 7:00 am EDT Data to be Presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting Demonstrate Ability of DecisionDx®-Melanoma and DecisionDx®-SCC to Inform Clinical Decision Making
Mar 11, 2022 7:00 am EST Independent Data Presented at Society for Surgical Oncology Conference Demonstrated DecisionDx®-Melanoma Outperforms T-Stage at Identifying Patients with Low Risk of Sentinel Lymph Node Positivity
